Finding a pathway for recovery
The prevalence and societal impact of substance use disorders (SUDs) is an acknowledged public health crisis.
While an imperfect measure of its impact on society, opioid overdose deaths can be viewed as the leading edge of this crisis. In a 12-month period, ending April 2019, it was estimated that 67,123 Americans died from an opioid overdose. While multiple medications are now available to treat opioid use disorders, given the prevalence and societal burden, additional well-tolerated and effective therapies are needed.
The PBC is developing monoclonal antibody (mAb)-based passive immunotherapies. This approach is based on complexing a drug of abuse in the periphery, thereby preventing it from reaching the central nervous system. This approach offers a high degree of specificity to drug abuse, can be administered in quantities to sustain amounts required for clinical efficacy in all patients and does not interfere with an individual’s ability to use any of the medications currently used to treat SUDs.